Ketamine for Depression: How It Works, Success Rates, and What to Expect

At a Glance
Ketamine works through a completely different brain pathway than traditional antidepressants. Instead of targeting serotonin, it blocks NMDA receptors and triggers a rapid burst of glutamate signaling that can lift severe depression within hours, not weeks. About 60-70% of people with treatment-resistant depression respond to ketamine therapy, making it one of the most significant breakthroughs in psychiatric medicine in decades.

Why Ketamine Is Different From Every Other Antidepressant

If you have tried two or more antidepressants without meaningful relief, you already know the frustration of waiting six to eight weeks for a medication that might not work. Traditional antidepressants (SSRIs, SNRIs, tricyclics) all operate on the same basic principle: they increase the availability of serotonin, norepinephrine, or both in the brain. The problem is that roughly 30% of people with major depressive disorder do not respond adequately to these medications.

Ketamine takes an entirely different approach. Originally developed as an anesthetic in the 1960s, it was approved by the FDA for surgical use and has been on the World Health Organization’s List of Essential Medicines for decades. Its antidepressant properties were first documented in a landmark 2000 study at Yale, and since then, research from the National Institute of Mental Health (NIMH), Mount Sinai, and dozens of other institutions has confirmed that ketamine can produce rapid, robust antidepressant effects.

The Science: NMDA Receptors and the Glutamate Theory

To understand why ketamine works so quickly, you need to know a bit about glutamate, the brain’s primary excitatory neurotransmitter. While serotonin gets most of the press coverage in depression discussions, glutamate is actually far more abundant and plays a central role in how brain cells communicate, form new connections, and adapt over time.

Here is what happens at the molecular level:

1. NMDA receptor blockade. Ketamine blocks a specific type of glutamate receptor called the NMDA receptor. This is its primary mechanism and the reason it was originally used as an anesthetic at higher doses.
2. Glutamate surge. Blocking NMDA receptors on inhibitory interneurons causes a paradoxical burst of glutamate release. Think of it as releasing the brakes on excitatory signaling.
3. AMPA receptor activation. This glutamate surge activates AMPA receptors, which triggers a cascade of downstream signaling events.
4. BDNF release and synaptogenesis. The AMPA activation stimulates the release of brain-derived neurotrophic factor (BDNF), a protein that promotes the growth of new synaptic connections. Research from Yale has shown that ketamine can increase synaptic density in the prefrontal cortex within 24 hours.
5. mTOR pathway activation. Ketamine activates the mechanistic target of rapamycin (mTOR) signaling pathway, which drives the production of proteins needed for new synaptic connections.

This is fundamentally different from SSRIs, which increase serotonin availability and then require weeks of downstream neuroplastic changes before patients feel better. Ketamine essentially jumpstarts the neuroplasticity process directly.

Response Rates: What the Research Shows

The clinical evidence for ketamine in depression is substantial and growing. Here are the key numbers clinicians and patients should know:

Key Response Rates

Treatment-resistant depression: 60-70% of patients show significant improvement after a series of IV ketamine infusions, according to pooled data from multiple clinical trials.

Speed of response: Many patients report improvement within 4-24 hours of their first infusion. A 2006 NIMH study found that 71% of patients with treatment-resistant depression responded within 24 hours.

Suicidal ideation: Ketamine has shown rapid anti-suicidal effects, often within hours. This is particularly significant because no other medication works this quickly for acute suicidality.

Remission rates: Approximately 30-40% of patients achieve full remission (not just response) after a standard course of treatment.

These numbers are remarkable when you consider that these are patients who have already failed multiple other treatments. For comparison, when a patient with treatment-resistant depression tries yet another SSRI or SNRI, the response rate drops to roughly 10-15%.

Forms of Ketamine Therapy: IV vs. Nasal Spray vs. Oral

Ketamine therapy is available in several forms, each with distinct advantages, limitations, and cost profiles. Understanding the differences is essential for making an informed treatment decision.

IV Ketamine Infusions

IV infusions remain the gold standard in terms of clinical evidence. The typical protocol involves 0.5 mg/kg infused over 40 minutes. The IV route offers precise dose control and nearly 100% bioavailability, meaning the full dose reaches the bloodstream. Most clinics follow a protocol of six infusions over two to three weeks for the initial treatment phase.

The main drawbacks are cost (insurance rarely covers IV ketamine for depression) and the requirement to visit a clinic for each session.

Spravato (Esketamine) Nasal Spray

Spravato is the S-enantiomer of ketamine, approved by the FDA in 2019 specifically for treatment-resistant depression and in 2020 for major depressive disorder with suicidal ideation. Because it carries FDA approval, insurance companies are more likely to cover it, though prior authorization requirements and high copays can still be barriers.

Patients must self-administer the nasal spray under supervision at a certified healthcare facility and remain for at least two hours of monitoring afterward. Sessions typically occur twice weekly for the first month, then weekly, then weekly or biweekly for maintenance.

Oral and Sublingual Ketamine

At-home ketamine therapy has grown rapidly, with several telehealth companies offering sublingual (under the tongue) ketamine lozenges or tablets prescribed by a physician after a virtual consultation. The lower bioavailability means higher doses are needed to achieve therapeutic effects, and the experience tends to be milder than IV infusions.

This option is the most affordable and convenient, but it also has the least clinical oversight during treatment. If you are considering at-home ketamine, look for programs that include regular check-ins with a clinician and ideally integration therapy or psychotherapy alongside the medication.

What a Typical Treatment Protocol Looks Like

While protocols vary by provider, here is a common framework for IV ketamine treatment:

Induction phase (weeks 1-3): Six IV infusions, typically scheduled two to three times per week. This is where most patients first notice improvement. Your provider will monitor vital signs throughout each 40-minute infusion.

Stabilization phase (weeks 4-8): If you responded to the initial series, you will likely receive one infusion per week for four to six weeks to consolidate the antidepressant effect.

Maintenance phase (ongoing): Many patients need periodic booster infusions to maintain their response. The frequency varies widely, from once every two weeks to once every few months. Your clinician will work with you to find the minimum effective frequency.

Who Responds Best to Ketamine?

Research has identified several factors that may predict a stronger response to ketamine therapy:

• Treatment-resistant depression. Paradoxically, patients who have failed multiple antidepressants often respond well to ketamine, precisely because it works through a different mechanism.
• Bipolar depression. Some studies suggest ketamine may be effective for the depressive phase of bipolar disorder, though this is an area of active research and requires careful monitoring.
• Depression with suicidal ideation. The rapid anti-suicidal effects make ketamine particularly valuable in acute situations where standard antidepressants are too slow.
• Depression with anxiety features. Several studies have found that patients with comorbid anxiety may actually respond better to ketamine than those with depression alone.
• Family history of alcohol use disorder. Interestingly, a 2019 study found that patients with a family history of alcohol use disorder had higher response rates to ketamine. This may relate to shared glutamate system genetics.

Patients with active substance use disorders, uncontrolled hypertension, or a history of psychosis may not be good candidates for ketamine therapy. A thorough psychiatric and medical evaluation should always precede treatment.

Side Effects During and After Infusion

Ketamine is generally well-tolerated at the sub-anesthetic doses used for depression, but it does produce noticeable effects during treatment. Knowing what to expect can help reduce anxiety about the process.

Common Side Effects During Infusion

Dissociation: A feeling of detachment from your body or surroundings. This is the most characteristic effect and usually resolves within 1-2 hours after the infusion ends.

Nausea: Occurs in roughly 10-15% of patients. Most clinics offer anti-nausea medication as a preventive measure.

Elevated blood pressure and heart rate: Temporary increases are common and monitored throughout the infusion. This is why uncontrolled hypertension is a contraindication.

Dizziness and blurred vision: Usually mild and short-lived.

Vivid perceptual changes: Some patients experience visual or auditory distortions. These are temporary and not harmful, but they can be unsettling if unexpected.

Most side effects resolve within one to two hours after treatment. You will not be able to drive yourself home, so plan for someone to pick you up or arrange a ride. Cognitive side effects (such as difficulty concentrating) are typically gone by the next day.

Long-term side effect concerns primarily relate to frequent, high-dose use. At the sub-anesthetic doses used for depression, serious complications like bladder toxicity (which has been reported in recreational ketamine users) are extremely rare. However, this is one reason why working with a qualified clinician and following an appropriate dosing schedule matters.

Ketamine vs. Traditional Antidepressants: A Quick Comparison

What the Latest Research Says

The field continues to evolve rapidly. Some of the most notable recent findings include:

• Yale research on synaptogenesis: Brain imaging studies have confirmed that ketamine increases synaptic connections in the prefrontal cortex of depressed patients, providing a biological explanation for its rapid effects.
• NIMH clinical trials: Multiple NIMH-funded studies have established the efficacy and safety of repeated ketamine infusions, moving the field beyond single-dose proof-of-concept work.
• Metabolite research: Researchers are studying hydroxynorketamine (HNK), a ketamine metabolite, as a potential next-generation antidepressant that might provide the benefits without dissociative effects.
• Combination with psychotherapy: Emerging evidence suggests that pairing ketamine with therapy (particularly cognitive behavioral therapy) during the window of enhanced neuroplasticity may produce longer-lasting results.

Is Ketamine Right for You?

Ketamine therapy is not a first-line treatment for depression. Current clinical guidelines generally recommend it after a patient has not responded adequately to at least two conventional antidepressants. However, if you are in that situation, the evidence strongly supports ketamine as a viable option worth discussing with your psychiatrist or primary care provider.

When evaluating ketamine clinics, look for providers who conduct thorough medical and psychiatric evaluations before treatment, monitor vital signs during infusions, have clear protocols for managing side effects, and integrate ketamine into a broader treatment plan that includes therapy and follow-up care.

Related Reading

• Ketamine Therapy: The Complete Patient Guide
• TMS Therapy: What to Know Before Your First Session
• Ketamine Therapy Cost: A Complete Price Breakdown
• Treatment-Resistant Depression: When Standard Medications Fail